Steven Sell compensation by year
agilon health Summary Compensation Table · all 6 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $432,692 | $750,000 | $750,000 | $750,000 | $750,000 | $431,507 |
| Bonus | — | $0 | $0 | $0 | $0 | $0 |
| Stock awards | — | $0 | $2,250,017 | $3,375,043 | $3,375,007 | $4,050,004 |
| Option awards | $5,277,000 | $0 | $4,500,031 | $1,125,008 | $1,125,002 | $2,250,001 |
| Non-equity incentive | $328,893 | $506,250 | $523,125 | $0 | $161,438 | $0 |
| Pension and deferred compensation | — | $0 | $0 | $0 | $0 | $0 |
| All other | — | $0 | $16,000 | $16,985 | $4,596 | $546,875 |
| Total | $6,038,585 | $1,256,250 | $8,039,173 | $5,267,036 | $5,416,043 | $7,278,387 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: agilon health, inc. DEF 14A filed April 22, 2026, accession 0001628280-26-026544, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 80,244 | — | $23.07 |
| Option | 500,000 | — | $10.12 |
| Option | 415,130 | — | $4.46 |
| Option | 400,000 | — | $4.50 |
| Option | 51,261 | — | $28.46 |
Per the Outstanding Equity Awards at Fiscal Year-End table in agilon health, inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments agilon health discloses, by trigger · FY2024| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $1,125,000 | — | $33,000 | $2,283,000 |
| Resignation for good reason, no change in control | $1,125,000 | — | $33,000 | $2,283,000 |
| Change in control and involuntary termination | — | $1,690,655 | — | $1,690,655 |
Per the Potential Payments Upon Termination or Change in Control table in agilon health, inc.'s FY2024 proxy. Estimates as the company printed them; a dash means it printed no figure.
agilon health’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Steven Sell · this page | Former Chief Executive Officer and President | $7,278,387 |
| Jeffrey Schwaneke | Chief Financial Officer and Interim Co-Principal Executive Officer | $5,610,878 |
| Benjamin Shaker | Chief Markets Officer and Interim Co-Principal Executive Officer | $5,357,548 |
| Denise Zamore | Chief Legal Officer and Corporate Secretary | $3,123,418 |
| Girish Venkatachaliah | Chief Technology Officer | $2,056,086 |
The full agilon health compensation record
free company briefThis page is one person within agilon health's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order agilon health's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are agilon health's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat